Cancer immunotherapy side effect research

Research into cancer immunotherapy, specifically immune checkpoint inhibitors, highlights both the efficacy of these treatments and the significant challenges posed by immune-related adverse events (irAEs). These treatments work by blocking proteins like PD-1 to allow the immune system to attack tumor cells, but they can also cause the immune system to attack healthy organs.

Studies indicate that side effects are common, with skin rashes affecting up to 70 percent of patients and colitis affecting between 8 percent and 27 percent. A multicentre cohort study of 612 patients reported that 244 individuals experienced 354 irAEs, with severe events leading to hospitalization or treatment discontinuation in half of those cases. Sixteen fatal events were recorded, primarily involving pneumonitis, colitis, or hepatitis.

To address the difficulty of managing and detecting these toxicities, researchers are investigating the use of agentic artificial intelligence. While large language model-based systems have shown promise in extracting details from unstructured clinical notes to improve the speed and consistency of toxicity curation, researchers noted that determining exact severity remains a challenge for AI.